James E. Dentzer
2008 - Amicus Therapeutics
In 2008, James E. Dentzer earned a total compensation of $774.7K as Chief Financial Officer at Amicus Therapeutics, a 21% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $79,506 |
|---|---|
| Option Awards | $291,334 |
| Salary | $296,940 |
| Stock Awards | $91,465 |
| Other | $15,500 |
| Total | $774,745 |
Dentzer received $296.9K in salary, accounting for 38% of the total pay in 2008.
Dentzer also received $79.5K in non-equity incentive plan, $291.3K in option awards, $91.5K in stock awards and $15.5K in other compensation.
Rankings
In 2008, James E. Dentzer's compensation ranked 5,170th out of 9,135 executives tracked by ExecPay. In other words, Dentzer earned more than 43.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,170 out of 9,135 | 43rd |
Division Manufacturing | 1,878 out of 3,436 | 45th |
Major group Chemicals And Allied Products | 376 out of 815 | 54th |
Industry group Drugs | 233 out of 597 | 61st |
Industry Pharmaceutical Preparations | 170 out of 408 | 58th |
Source: SEC filing on April 24, 2009.
Dentzer's colleagues
We found four more compensation records of executives who worked with James E. Dentzer at Amicus Therapeutics in 2008.